ATE178801T1 - Tgf-beta zur verbesserung der regeneration von neuronalem gewebe - Google Patents

Tgf-beta zur verbesserung der regeneration von neuronalem gewebe

Info

Publication number: ATE178801T1
Authority: AT; Austria
Prior art keywords: tgf; beta; neuronal tissue; improve regeneration; nervous system
Prior art date: 1991-11-22

Application number

AT92925330T

Other languages

English (en)

Inventor

Peter Gluckman

Karoly Nikolics

Christopher Williams

Original Assignee

Genentech Inc

Auckland Uniservices Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-11-22

Filing date

1992-11-20

Publication date

1999-04-15

1992-11-20 Application filed by Genentech Inc, Auckland Uniservices Ltd filed Critical Genentech Inc

1999-04-15 Application granted granted Critical

1999-04-15 Publication of ATE178801T1 publication Critical patent/ATE178801T1/de

Links

230000001537 neural effect Effects 0.000 title 1
230000008929 regeneration Effects 0.000 title 1
238000011069 regeneration method Methods 0.000 title 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title 1
102000046299 Transforming Growth Factor beta1 Human genes 0.000 abstract 3
101800002279 Transforming growth factor beta-1 Proteins 0.000 abstract 3
210000003169 central nervous system Anatomy 0.000 abstract 3
208000027418 Wounds and injury Diseases 0.000 abstract 2
230000006378 damage Effects 0.000 abstract 2
208000014674 injury Diseases 0.000 abstract 2
208000001738 Nervous System Trauma Diseases 0.000 abstract 1
208000012902 Nervous system disease Diseases 0.000 abstract 1
208000028412 nervous system injury Diseases 0.000 abstract 1
229940099456 transforming growth factor beta 1 Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT92925330T 1991-11-22 1992-11-20 Tgf-beta zur verbesserung der regeneration von neuronalem gewebe ATE178801T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
NZ24069691		1991-11-22

Publications (1)

Publication Number	Publication Date
ATE178801T1 true ATE178801T1 (de)	1999-04-15

Family

ID=19923808

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT92925330T ATE178801T1 (de)	1991-11-22	1992-11-20	Tgf-beta zur verbesserung der regeneration von neuronalem gewebe

Country Status (9)

Country	Link
EP (1)	EP0625050B1 (de)
JP (2)	JP4101284B2 (de)
AT (1)	ATE178801T1 (de)
CA (1)	CA2122058C (de)
DE (1)	DE69228949T2 (de)
DK (1)	DK0625050T3 (de)
ES (1)	ES2133333T3 (de)
GR (1)	GR3030651T3 (de)
WO (1)	WO1993009802A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6150328A (en)	1986-07-01	2000-11-21	Genetics Institute, Inc.	BMP products
US5851832A (en) *	1991-07-08	1998-12-22	Neurospheres, Ltd.	In vitro growth and proliferation of multipotent neural stem cells and their progeny
US7361505B1 (en)	1991-07-08	2008-04-22	Neurospheres Holdings Ltd.	Multipotent neural stem cell compositions
US6497872B1 (en)	1991-07-08	2002-12-24	Neurospheres Holdings Ltd.	Neural transplantation using proliferated multipotent neural stem cells and their progeny
US6399369B1 (en)	1991-07-08	2002-06-04	Neurospheres Holdings Ltd.	Multipotent neural stem cell cDNA libraries
US6071889A (en) *	1991-07-08	2000-06-06	Neurospheres Holdings Ltd.	In vivo genetic modification of growth factor-responsive neural precursor cells
US6294346B1 (en)	1991-07-08	2001-09-25	Neurospheres Holdings, Ltd.	Use of multipotent neural stem cells and their progeny for the screening of drugs and other biological agents
US7166277B1 (en)	1991-07-08	2007-01-23	Neurospheres Holdings Ltd.	Remyelination of neurons using multipotent neural stem cell progeny
US5980885A (en) *	1991-07-08	1999-11-09	Neurospheres Holdings Ltd.	Growth factor-induced proliferation of neural precursor cells in vivo
US5750376A (en) *	1991-07-08	1998-05-12	Neurospheres Holdings Ltd.	In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US6395494B1 (en)	1993-05-13	2002-05-28	Neorx Corporation	Method to determine TGF-β
US6291206B1 (en)	1993-09-17	2001-09-18	Genetics Institute, Inc.	BMP receptor proteins
EP0733109B9 (de)	1993-12-07	2006-07-05	Genetics Institute, LLC	Bmp-12, bmp-13 und diese enthaltende sehne-induzierende zusammensetzungen
US5650396A (en) *	1994-03-15	1997-07-22	Celtrix Pharmaceuticals, Inc.	Methods of modulating inflammatory cytokines in the CNS using TGF-β
DE69723429T3 (de) *	1996-03-22	2007-09-20	Curis, Inc., Cambridge	Verfahren zur verbesserten funktionellen Erholung der motorischen Koordination, der Sprache oder Sinneswahrnehmung nach Trauma oder Ischämie des ZNS
US7544511B2 (en)	1996-09-25	2009-06-09	Neuralstem Biopharmaceuticals Ltd.	Stable neural stem cell line methods
CA2296056A1 (en) *	1997-07-10	1999-01-21	Keith Baker	Methods for universally distributing therapeutic agents to the brain
US5968829A (en) *	1997-09-05	1999-10-19	Cytotherapeutics, Inc.	Human CNS neural stem cells
US6727224B1 (en)	1999-02-01	2004-04-27	Genetics Institute, Llc.	Methods and compositions for healing and repair of articular cartilage
WO2001028602A1 (en)	1999-10-15	2001-04-26	Genetics Institute, Inc.	Formulations of hyaluronic acid for delivery of osteogenic proteins
US6613083B2 (en)	2001-05-02	2003-09-02	Eckhard Alt	Stent device and method
CA2449008A1 (en)	2001-06-01	2002-12-12	Wyeth	Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
TWI267378B (en)	2001-06-08	2006-12-01	Wyeth Corp	Calcium phosphate delivery vehicles for osteoinductive proteins
US8293488B2 (en)	2002-12-09	2012-10-23	Neuralstem, Inc.	Method for screening neurogenic agents
WO2004053071A2 (en)	2002-12-09	2004-06-24	Judith Kelleher-Andersson	Method for discovering neurogenic agents
DK1758986T3 (en)	2004-06-09	2016-01-18	Univ Edinburgh	Neural stem cells
CN101084303A (zh)	2004-11-17	2007-12-05	神经干公司	用于治疗神经变性症状的人类神经细胞的移植
US20100158878A1 (en)	2008-12-23	2010-06-24	Alexandra Capela	Target populations of oligodendrocyte precursor cells and methods of making and using same
CA2806904C (en)	2010-07-28	2018-11-27	Neuralstem, Inc.	Methods for treating and/or reversing neurodegenerative diseases and/or disorders
WO2016064737A1 (en)	2014-10-20	2016-04-28	Neuralstem, Inc.	Stable neural stem cells comprising an exogenous polynucleotide coding for a growth factor and methods of use thereof

1992
- 1992-11-20 AT AT92925330T patent/ATE178801T1/de active
- 1992-11-20 EP EP92925330A patent/EP0625050B1/de not_active Expired - Lifetime
- 1992-11-20 DK DK92925330T patent/DK0625050T3/da active
- 1992-11-20 JP JP50951593A patent/JP4101284B2/ja not_active Expired - Lifetime
- 1992-11-20 CA CA002122058A patent/CA2122058C/en not_active Expired - Lifetime
- 1992-11-20 ES ES92925330T patent/ES2133333T3/es not_active Expired - Lifetime
- 1992-11-20 WO PCT/US1992/009974 patent/WO1993009802A2/en not_active Ceased
- 1992-11-20 DE DE69228949T patent/DE69228949T2/de not_active Expired - Lifetime
1999
- 1999-06-30 GR GR990401737T patent/GR3030651T3/el unknown
2003
- 2003-11-13 JP JP2003384121A patent/JP2004115532A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
DE69228949D1 (de)	1999-05-20
EP0625050B1 (de)	1999-04-14
EP0625050A1 (de)	1994-11-23
WO1993009802A2 (en)	1993-05-27
JP2004115532A (ja)	2004-04-15
JP4101284B2 (ja)	2008-06-18
JPH07501080A (ja)	1995-02-02
GR3030651T3 (en)	1999-10-29
DE69228949T2 (de)	1999-09-16
CA2122058A1 (en)	1993-05-27
CA2122058C (en)	2001-07-31
DK0625050T3 (da)	1999-10-25
ES2133333T3 (es)	1999-09-16

Legal Events

Date	Code	Title	Description
1999-11-15	UEP	Publication of translation of european patent specification

Publication	Publication Date	Title
ATE178801T1 (de)	1999-04-15	Tgf-beta zur verbesserung der regeneration von neuronalem gewebe
DE69232008D1 (de)	2001-09-20	Verwendung von insulinähnlichen Wachstumsfaktoren und Analogen zur BEHANDLUNG VON ERKRANKUNGEN DER SEHNERVEN
PT646012E (pt)	2003-03-31	Cura de feridas e tratamento de perturbacoes fibroticas por tgfbeta-3
ATE207352T1 (de)	2001-11-15	Nicht-allosterische gaba a agonisten zur behandlung von schlafstörungen
DE69739792D1 (de)	2010-04-15	Verfahren zur Behandlung von Augenerkrankungen
ATE271874T1 (de)	2004-08-15	Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronen
SE8703625D0 (sv)	1987-09-18	New medical use
WO1995017154A3 (en)	1995-07-13	Use of thalidomide for treating neurocognitive disorders
KR890700033A (ko)	1989-03-02	외상치료 및 뼈 재생
ATE110958T1 (de)	1994-09-15	Verwendung von sertralin zur behandlung verfrühter ejakulation.
ATE137965T1 (de)	1996-06-15	Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
DE3786893D1 (de)	1993-09-09	Piperidinderivat zur schmerzbehandlung.
ATE191849T1 (de)	2000-05-15	Verwendung von (s)-(-)-alpha-ethyl-2-oxo-1- pyrrolidinacetamid zur herstellung eines medikaments zur behandlung von angst
ATE307203T1 (de)	2005-11-15	Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
DE69800859D1 (de)	2001-07-05	Verwendung von Moxonidin zur Behandlung neuropathischer Schmerzen
ATE222491T1 (de)	2002-09-15	Melatonin-derivate zur verwendung in der behandlung von schlafstörungen
EP0630412A4 (de)	1994-06-02	Verfahren zur erkennung und behandlung anomaler zellen.
ATE281841T1 (de)	2004-11-15	Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
DE69301750D1 (de)	1996-04-18	Verwendung von 1-Alpha,24(R)-Dihydroxy-22(E)-Dehydrovitamin-D3 zur Herstellung eines Arzneimittels zur Behandlung der Osteoporose
DE69210286D1 (de)	1996-06-05	Behandlung von intraocularem Druck mit einer synergistischen Kombination
RU97101420A (ru)	1998-09-10	Способ лечения тонзиллита
ATE306278T1 (de)	2005-10-15	Behandlung von knochenleiden mit adrenomedullin
RU96124676A (ru)	1999-02-10	Способ хирургического лечения осложненных форм отслоек сетчатки
DE69941134D1 (de)	2009-08-27	Verwendung von R (+)- g(a)-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol zur Behandlung von Schlafstörungen
DE3685988D1 (de)	1992-08-20	Verwendung von "naftidrofuryl" zur behandlung von neuropathien.